Kelly Dooley, MD, PhD

Faculty

Titles:

Associate Professor, Medicine and Pharmacology and Molecular Sciences

Email:

kdooley1@jhmi.edu

SciVal:

SciVal Link

Research focuses on clinical pharmacology of new anti-tuberculosis regimens with an emphasis on: (1) Phase I clinical trials of new or existing anti-TB drugs including dose escalation trials and studies of drug-drug interactions between anti-TB agents and antiretrovirals to treat HIV; (2) Use of PK/PD analysis and modelling in Phase II tuberculosis clinical treatment trials to determine concentration-effect relationships that will allow for optimization of dosing; and (3) Evaluation of TB and HIV drug concentrations in special populations, such as pregnant women and children; (4) Evaluation of treatment-shortening regimens for drug-sensitive TB and investigational regimens for treatment of multidrug-resistant TB; and (5) Translational work involving novel animal models of cavitary pulmonary TB disease to understand drug distribution in diseased lung.

Categories

Events

«

August 2022

»
S
M
T
W
T
F
S
·
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
·
·
·

Projects

Human-centered Design and Communities of...

The goal of this project is to use local communities of practice and the emerging technique of human-centered design to improve...

Read More

TB Modeling and Analysis Consortium (TB MAC)

Dr. Dowdy serves on the steering committee of an international consortium of TB modelers that aims to improve approaches to TB...

Read More

Statins as Adjunctive, Host-Directed Therapy...

The goal of this study is to investigate the potential utility of pravastatin as an adjunctive, host-directed therapy for...

Read More

Comparative implementation and...

We are conducting a randomized comparative implementation trial across 56 sites in rural South Africa to evaluate three...

Read More